← Back to Search

Monoclonal Antibodies

DSC-MRI for Recurrent Glioblastoma

N/A
Recruiting
Led By Jerrold Boxerman
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients not previously treated with immunotherapies
Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
Must not have
Patient not eligible if primarily receiving bevacizumab for reasons other than tumor treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.

Who is the study for?
This trial is for adults with recurrent glioblastoma who can undergo MRI scans and have not been treated with immunotherapies. They must have a Karnofsky performance status of at least 70, no severe allergies to gadolinium, no MR-incompatible implants, and adequate organ function. Pregnant or breastfeeding women are excluded.
What is being tested?
The study tests how well DSC-MRI measures blood volume changes in the brain as an early indicator of response to Bevacizumab treatment in patients experiencing their first recurrence of glioblastoma.
What are the potential side effects?
While this trial focuses on imaging rather than drug effects, Bevacizumab may cause headaches, high blood pressure, bleeding problems, tiredness, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never received immunotherapy treatments.
Select...
My initial surgery confirmed I have glioblastoma or gliosarcoma.
Select...
I am able to care for myself but may not be able to do active work.
Select...
I can have a small needle placed in my vein for treatment.
Select...
I can safely receive IV contrast.
Select...
My kidneys work well (eGFR >= 40).
Select...
I am scheduled for treatment with a standard dose of bevacizumab.
Select...
I am not pregnant or breastfeeding.
Select...
My low-grade brain tumor has transformed into a high-grade tumor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not taking bevacizumab for reasons unrelated to cancer treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in rCBV within enhancing tumor
OS
Secondary study objectives
CBF
Change in CBF
PFS
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (DSC-MRI)Experimental Treatment1 Intervention
Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
2006
Completed Early Phase 1
~220

Find a Location

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
121 Previous Clinical Trials
180,051 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,111,947 Total Patients Enrolled
5 Trials studying Gliomas
292 Patients Enrolled for Gliomas
Jerrold BoxermanPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03115333 — N/A
Gliomas Research Study Groups: Diagnostic (DSC-MRI)
Gliomas Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT03115333 — N/A
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03115333 — N/A
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top